Lacosamide Accord (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilising neuronal membranes and reducing repetitive firing. It also binds to the protein CRMP‑2, influencing neuronal differentiation and axonal growth. These actions together lower neuronal hyper‑excitability, providing an anticonvulsant effect in focal seizure disorders.

The appropriate dose of Lacosamide Accord is determined by the prescribing clinician based on the patient’s age, weight, renal function, and response to therapy. Dosing regimens are individualized and should follow the prescriber’s instructions and local clinical guidelines.

Safety data for lacosamide during pregnancy and lactation are limited, and the medication is classified as having an unknown pregnancy category. Clinicians must weigh potential benefits against possible risks, and use the drug only if clearly needed. Breastfeeding mothers should consult their healthcare provider.

To order Lacosamide Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The team then provides pricing, availability, shipping details (including cold‑chain if required) and assists with import documentation.

Lacosamide’s mechanism—enhancing slow sodium‑channel inactivation and binding CRMP‑2—differs from traditional sodium‑channel blockers such as carbamazepine, which primarily affect fast inactivation. This distinct profile may offer benefit for patients who do not respond adequately to older agents, though comparative efficacy and tolerability should be evaluated by the treating physician.

Lacosamide Accord should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the vials in their original packaging until use to maintain stability and ensure proper handling in accordance with the product’s labeling.

Lacosamide Accord is given as an intravenous injection by a qualified healthcare professional. The infusion rate and volume are determined by the prescriber, typically administered over a controlled period to minimise infusion‑related reactions. Monitoring of vital signs and cardiac rhythm is recommended during administration.

Serious risks include cardiac arrhythmias such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, respiratory depression especially with rapid infusion, and the emergence of suicidal thoughts or behaviors. Patients should be monitored closely for these events, and any concerning symptoms should prompt immediate medical evaluation.

Lacosamide Accord should be avoided in individuals with known hypersensitivity to lacosamide or any excipients in the formulation. Caution is also advised for patients with significant cardiac conduction abnormalities, severe renal impairment, or those taking medications that strongly inhibit CYP3A4, unless supervised by a specialist.